Leiden University Medical Centre (LUMC), the DanStem Institute at the University of Copenhagen and the Murdoch Children's Research Institute in Melbourne will jointly receive 300 million euros from the Novo Nordisk Foundation. The aim of this new international consortium is to bring stem cell based therapies from the laboratory to the patient.
Professor Ton Rabelink (LUMC) comments: ‘This is wonderful for the further development of regenerative medicine in The Netherlands and in Leiden in particular. Years of strategic investments in top-notch regenerative medicine research, which started with the Dutch Research Agenda, is paying off. But not only that: being part of RegMed XB, building the RegMed XB pilot factory and having Necstgen in Leiden contributes to the strong and credible proposition we can offer to partners in regenerative medicine in Europe and abroad”.
Stem cells offer a unique opportunity to repair tissue damaged by disease or trauma. The potential use is promising for the treatment of diabetes, metabolic diseases and inherited disorders, but substantial work is still needed to bring these stem cell therapies to patients. To accelerate this, the Novo Nordisk Foundation is investing around 100 million euros in each institute forming the new reNEW consortium. The funding is for a period of 10 years.